These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
551 related articles for article (PubMed ID: 10833208)
1. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. Feagan BG; Fedorak RN; Irvine EJ; Wild G; Sutherland L; Steinhart AH; Greenberg GR; Koval J; Wong CJ; Hopkins M; Hanauer SB; McDonald JW N Engl J Med; 2000 Jun; 342(22):1627-32. PubMed ID: 10833208 [TBL] [Abstract][Full Text] [Related]
2. Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. Feagan BG; Rochon J; Fedorak RN; Irvine EJ; Wild G; Sutherland L; Steinhart AH; Greenberg GR; Gillies R; Hopkins M N Engl J Med; 1995 Feb; 332(5):292-7. PubMed ID: 7816064 [TBL] [Abstract][Full Text] [Related]
3. A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group. Thomsen OO; Cortot A; Jewell D; Wright JP; Winter T; Veloso FT; Vatn M; Persson T; Pettersson E N Engl J Med; 1998 Aug; 339(6):370-4. PubMed ID: 9691103 [TBL] [Abstract][Full Text] [Related]
4. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. Targan SR; Hanauer SB; van Deventer SJ; Mayer L; Present DH; Braakman T; DeWoody KL; Schaible TF; Rutgeerts PJ N Engl J Med; 1997 Oct; 337(15):1029-35. PubMed ID: 9321530 [TBL] [Abstract][Full Text] [Related]
5. Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group. Greenberg GR; Feagan BG; Martin F; Sutherland LR; Thomson AB; Williams CN; Nilsson LG; Persson T N Engl J Med; 1994 Sep; 331(13):836-41. PubMed ID: 8078529 [TBL] [Abstract][Full Text] [Related]
6. Methotrexate in Crohn's disease: results of a randomized, double-blind, placebo-controlled trial. Arora S; Katkov W; Cooley J; Kemp JA; Johnston DE; Schapiro RH; Podolsky D Hepatogastroenterology; 1999; 46(27):1724-9. PubMed ID: 10430331 [TBL] [Abstract][Full Text] [Related]
7. Low-dose cyclosporine for the treatment of Crohn's disease. The Canadian Crohn's Relapse Prevention Trial Investigators. Feagan BG; McDonald JW; Rochon J; Laupacis A; Fedorak RN; Kinnear D; Saibil F; Groll A; Archambault A; Gillies R N Engl J Med; 1994 Jun; 330(26):1846-51. PubMed ID: 8196727 [TBL] [Abstract][Full Text] [Related]
8. Methotrexate as single therapy in Crohn's disease: is its long-term efficacy limited? Charpignon C; Beau P Gastroenterol Clin Biol; 2008 Feb; 32(2):153-7. PubMed ID: 18343615 [TBL] [Abstract][Full Text] [Related]
9. Methotrexate in Crohn's disease: long-term efficacy and toxicity. Lémann M; Zenjari T; Bouhnik Y; Cosnes J; Mesnard B; Rambaud JC; Modigliani R; Cortot A; Colombel JF Am J Gastroenterol; 2000 Jul; 95(7):1730-4. PubMed ID: 10925976 [TBL] [Abstract][Full Text] [Related]
10. Etanercept plus standard therapy for Wegener's granulomatosis. Wegener's Granulomatosis Etanercept Trial (WGET) Research Group N Engl J Med; 2005 Jan; 352(4):351-61. PubMed ID: 15673801 [TBL] [Abstract][Full Text] [Related]
11. A comparison of budesonide with prednisolone for active Crohn's disease. Rutgeerts P; Löfberg R; Malchow H; Lamers C; Olaison G; Jewell D; Danielsson A; Goebell H; Thomsen OO; Lorenz-Meyer H N Engl J Med; 1994 Sep; 331(13):842-5. PubMed ID: 8078530 [TBL] [Abstract][Full Text] [Related]
12. Natalizumab for active Crohn's disease. Ghosh S; Goldin E; Gordon FH; Malchow HA; Rask-Madsen J; Rutgeerts P; Vyhnálek P; Zádorová Z; Palmer T; Donoghue S; N Engl J Med; 2003 Jan; 348(1):24-32. PubMed ID: 12510039 [TBL] [Abstract][Full Text] [Related]
13. Effect of an enteric-coated fish-oil preparation on relapses in Crohn's disease. Belluzzi A; Brignola C; Campieri M; Pera A; Boschi S; Miglioli M N Engl J Med; 1996 Jun; 334(24):1557-60. PubMed ID: 8628335 [TBL] [Abstract][Full Text] [Related]
15. Beclomethasone dipropionate in Crohn's ileitis: a randomised, double-blind trial. Prantera C; Rizzi M; Cottone M; Casa A; Annese V; Sturniolo GC; Marconi S; Lochs H Dig Liver Dis; 2011 Jun; 43(6):459-64. PubMed ID: 21215714 [TBL] [Abstract][Full Text] [Related]
16. [A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators]. Martreau P Gastroenterol Clin Biol; 2000 Dec; 24(12):1243-4. PubMed ID: 11277090 [No Abstract] [Full Text] [Related]
17. A multicenter, randomized, double-blind trial of everolimus versus azathioprine and placebo to maintain steroid-induced remission in patients with moderate-to-severe active Crohn's disease. Reinisch W; Panés J; Lémann M; Schreiber S; Feagan B; Schmidt S; Sturniolo GC; Mikhailova T; Alexeeva O; Sanna L; Haas T; Korom S; Mayer H Am J Gastroenterol; 2008 Sep; 103(9):2284-92. PubMed ID: 18671816 [TBL] [Abstract][Full Text] [Related]
18. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Targan SR; Feagan BG; Fedorak RN; Lashner BA; Panaccione R; Present DH; Spehlmann ME; Rutgeerts PJ; Tulassay Z; Volfova M; Wolf DC; Hernandez C; Bornstein J; Sandborn WJ; Gastroenterology; 2007 May; 132(5):1672-83. PubMed ID: 17484865 [TBL] [Abstract][Full Text] [Related]
19. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. Pagnoux C; Mahr A; Hamidou MA; Boffa JJ; Ruivard M; Ducroix JP; Kyndt X; Lifermann F; Papo T; Lambert M; Le Noach J; Khellaf M; Merrien D; Puéchal X; Vinzio S; Cohen P; Mouthon L; Cordier JF; Guillevin L; N Engl J Med; 2008 Dec; 359(26):2790-803. PubMed ID: 19109574 [TBL] [Abstract][Full Text] [Related]